Vistagen Therapeutics Faces Class Action Lawsuit: Shareholder Alert and Deadlines

Overview

The Gross Law Firm has issued a pressing notice for investors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) regarding a class action lawsuit related to significant financial losses suffered by shareholders. Investors who acquired shares during the specified class period are encouraged to act swiftly to safeguard their interests.

Class Action Details

The class action lawsuit encompasses those who purchased Vistagen stock from April 1, 2024 to December 16, 2025. The case arises from allegations that the company made overly optimistic statements about its investigational product, fasedienol, intended for the treatment of social anxiety disorder. While promoting the potential of fasedienol, the company reportedly withheld crucial adverse facts related to the Phase 3 PALISADE-3 trial. This trial notably failed to demonstrate significant efficacy, leading to a sharp decline in the company's stock price—from $4.36 on December 16, 2025, to just $0.86 the following day, marking over an 80% drop.

Why This Matters?

The allegations detail that while the defendants—the company executives—projected a positive outlook about the drug’s trials, they simultaneously suppressed significant negative data. The implication is clear: their actions may have artificially inflated the stock price, misleading investors and causing severe financial loss when the truth was revealed.

Important Dates

Investors should be mindful that the deadline for registering in this class action as a potential lead plaintiff is March 16, 2026. It is important for affected shareholders to register as soon as possible to ensure they are included in the recovery process.

How to Participate

Shareholders who believe they are eligible are encouraged to register their information through the Gross Law Firm’s dedicated platform. By doing this, they will gain access to important updates related to their case and the ongoing litigation. Notably, there is no obligation or cost associated with participating in this class action.

Commitment to Investors

The Gross Law Firm prides itself on advocating for the rights of investors adversely affected by deceitful practices and for promoting corporate responsibility. Their mission emphasizes the recovery of losses incurred due to misleading statements and fraudulent activities by corporate entities.

Final Note

As Vistagen Therapeutics continues to navigate through this legal matter, shareholders are called to action. Registering for the class action not only helps to protect individual interests but also supports a broader initiative to hold corporations accountable for their responsibilities to investors. If you have lost money while investing in Vistagen, you are encouraged to reach out and explore your legal options, ensuring your voice is heard in this pivotal case.

For further information or to initiate your registration for the class action, please contact the Gross Law Firm directly at their office located in New York, NY or through their online submission form.